E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10039083 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine if the study drug ANTIRIN® is at least as effective (non-inferiority testing) assessed by TNSS changes after 4 days of therapy as the comparative product NASIC® in the treatment of acute viral rhinitis, to compare ANTIRIN® with placebo to proof of its efficacy and to compare NASIC® with placebo to proof assay sensitivity. |
|
E.2.2 | Secondary objectives of the trial |
To determine efficacy assessed by VAS changes mearusing intensity of all individual symptoms (runny nose, sneezing, nasal itching and congestion) To determine the safety and tolerability of ANTIRIN®.
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
• established diagnosis of acute viral rhinitis. All following criteria must be met: o development of nasal symptoms within 24 hours o presence of nasal symptoms- congestion, rhinorrhea, nasal mucosa irritation ( itching or sneezing). o overall viral symptoms (at least one of them should be present) – weakness, headache, myalgia, arthralgia. (Febrile patients are not excluded from the trial.) • patients between 18 – 60 years, both sexes. • written informed consent obtained . • TNSS score on inclusion ( day 0) ≥ 5. • the patient can be contacted by phone
|
|
E.4 | Principal exclusion criteria |
• Patients with history of allergic rhinitis, rhinitis sicca or rhinitis medicamentosa • pregnant or lactating women • patients with the history of bronchial asthma • patients with history of nose surgery, after the injury of the facial skelet, after actinotherapy of the facial region • patients with the history of endocrine disease • patients with the history of narrow angle glaucoma • patients taking the following drugs: o systemic corticosteroid drugs within 1 month prior inclusion o locally administered corticosteroid drugs within 7 days prior inclusion o antihypertensive drugs that may influence nasal congestion within 7 days prior inclusion ( beta blockers, ACE inhibitors, alpha adrenergic antagonists i.e. prazosin,) o use of any other nasal decongestant drugs orally or locally ( e.g. intransally) within 3 days prior inclusion o MAO inhibitors and other drugs with hypertensive potential within 7 days prior inclusion • patients with the history of nasal polyps • any other disease or condition which may interfere with study assessments as judged by the investigator • alcohol or drug abuse • patients taking part in any other clinical trial or having participated in a clinical trial within the previous 3 months • patients with history of hypersensitivity to the study drug or its excipients • clinically significant renal/hepatic impairment or serious heartdisease and uncontrolled hypertension • patients with pheochromocytoma • patients presenting any malignant disease • patients likely not to comply with the study procedures or with difficulties to understand the study procedures as judged by the investigator
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary efficacy parameter will be the absolute change from baseline to Day 4 in patient self-rated TNSS. The TNSS include a composite score of runny nose, sneezing, nasal itching and congestion. All symptoms are rated using four-point scale with following interpretation: 0 = absent symptoms (no sign/symptom evident) 1 = mild symptoms (sign/symptom clearly present, but minimal awareness; easily tolerated) 2 = moderate symptoms (definite awareness of sign/symptom that is bothersome but tolerable) 3 = severe symptoms (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) The baseline value for TNSS is defined as the last measurement taken prior to application of test/reference drug. Day 4 assessment of TNSS was defined as endpoint (LOCF imputation technique will be used on ITT set).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 6 |